Company intelligence / Profile preview

Tulani

Ownership: Private
Development stage: Other

Overview

Tulavi Therapeutics has developed a fully absorbable, hydrophilic material that forms an in situ protective layer over repaired nerves. This device is designed to reduce neuroma risk, accommodate swelling, support tissue gliding and post-op mobilization, and promote optimal healing by permitting nutrient exchange while inhibiting unwanted cell migration. The absorption rate of the material is matched to the specific healing profile of each treated nerve. No published clinical trial results are referenced.

Therapeutic areas: Neurology
Modalities: DeviceBiomaterial-based therapy
Industry: Surgical Medical Devices

Beyond the preview

Go deeper on Tulani.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Tulani.

Explore the full profile